Analyzing Kiora Pharmaceuticals (NASDAQ:KPRX) and Cansortium (OTCMKTS:CNTMF)

Cansortium (OTCMKTS:CNTMF) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Cansortium and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cansortium	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Institutional & Insider Ownership

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Cansortium and Kiora Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cansortium	N/A	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals	$16.02 million	0.71	-$10.84 million	($2.71)	-0.94

Cansortium has higher earnings, but lower revenue than Kiora Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cansortium and Kiora Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cansortium	0	0	0	0	0.00
Kiora Pharmaceuticals	1	1	1	0	2.00

Kiora Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 290.62%. Given Kiora Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Cansortium.

Summary

Kiora Pharmaceuticals beats Cansortium on 6 of the 8 factors compared between the two stocks.

About Cansortium

Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. The company's medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, and edibles under the Fluent brand name. It also sells various third-party branded medical cannabis products. The company was incorporated in 2018 and is headquartered in Miami, Florida.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.